ImmuPharma (LON:IMM) Trading Down 4.8% – Time to Sell?

ImmuPharma plc (LON:IMM) shares traded down 4.8% during mid-day trading on Wednesday . The company traded as low as GBX 2.66 ($0.04) and last traded at GBX 2.85 ($0.04). 5,267,162 shares traded hands during trading, a decline of 40% from the average session volume of 8,756,827 shares. The stock had previously closed at GBX 3 ($0.04).

ImmuPharma Stock Performance

The stock’s fifty day moving average is GBX 2.90 and its two-hundred day moving average is GBX 2.73. The firm has a market capitalization of £11.99 million, a price-to-earnings ratio of -4.88 and a beta of 1.53.

ImmuPharma (LON:IMM) last posted its quarterly earnings data on Monday, May 19th. The company reported GBX (0.60) (($0.01)) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.